Table 8.
Multivariate logistic regression analysis on factors associated with experiencing side effects of the vaccine.
| Model | Unstandardised Coefficients | Standardised Coefficients | p-value | |
|---|---|---|---|---|
| B | Std. Error | Beta | ||
| (Constant) | 6.224 | 0.848 | 0.000 | |
| Age | −0.750 | 0.141 | −0.204 | <0.001 |
| Gender | −0.266 | 0.214 | −0.048 | 0.215 |
| Hypertension | −0.101 | 0.121 | −0.036 | 0.401 |
| Diabetes mellitus | −0.392 | 0.239 | −0.173 | 0.324 |
| Vaccination | −0.038 | 0.163 | −0.009 | 0.814 |
| Rheumatoid arthritis | 0.592 | 0.216 | 0.322 | 0.068 |
| Non inflammatory/mechanical RMDs | 0.543 | 0.094 | 0.327 | 0.059 |
| Axial SpA | 0.214 | 0.101 | 0.611 | 0.143 |
| Vasculitis | 0.094 | 0.032 | 0.021 | 0.856 |
| SLE | 0.153 | 0.045 | 0.043 | 0.766 |
| Disease Activity at time of vaccination | −0.231 | 0.453 | −0.238 | 0.496 |
| Drug exposure | −0.043 | 0.022 | −0.032 | 0.231 |
| Steroid | 0.674 | 0.119 | 0.491 | 0.623 |
| Steroid dose | 0.083 | 0.084 | 0.045 | 0.322 |
| TNF- inhibitors | 0.043 | 0.112 | 0.074 | 0.123 |
| Methotrexate | 0.327 | 0.054 | 0.192 | 0.871 |
| Azathioprine | 0.656 | 0.210 | 0.439 | 0.073 |
| Hydroxychloroquine | 0.385 | 0.134 | 0.346 | 0.306 |
| Rituximab | 0.270 | 0.097 | 0.231 | 0.198 |
| Leflunomide | 0.328 | 0.178 | 0.411 | 0.174 |
| Mycophenolate | 0.376 | 0.044 | 0.276 | 0.099 |
| Sulfasalazine | 0.402 | 0.361 | 0.402 | 0.219 |
| Cyclophosphamide | 0.199 | 0.472 | 0.338 | 0.111 |
| Cyclosporine | 0.112 | 0.365 | 0.322 | 0.067 |
RMDs: rheumatic and musculoskeletal diseases; SpA: spondyloarthritis; SLE: systemic lupus erythematosus.